Rai Pragya, Zhao Xiaohui, Sambamoorthi Usha
J Pain Palliat Care Pharmacother. 2018 Jun-Sep;32(2-3):90-97. doi: 10.1080/15360288.2018.1546789. Epub 2019 Jan 24.
The purpose of this study was to examine the association of dipeptidyl peptidase-4 inhibitors (DPP4Is) with joint pain in adults with type 2 diabetes mellitus (T2DM). This was a retrospective cross-sectional study design, pooling data from the 2012 and 2014 Medical Expenditure Panel Survey. The sample consisted of 4,559 T2DM patients older than 40 years with (n = 3,224) or without joint pain (n = 1,335). Chi-square test and logistic regression were used to describe association of DPP4I use with joint pain. Among adults with T2DM, 70.7% reported physician-diagnosed joint pain. There were no significant differences in DPP4I use among those with and without joint pain (7.8% vs 6.3%). Even after adjusting for other factors that may affect DPP4I use, there was not a statistically significant difference in DPP4I use among adults with T2DM with and without joint pain (AOR = 1.04; 95% CI, 0.74-1.48). Adults with public health insurance (AOR = 1.76; 95% CI, 1.01-3.04), with prescription insurance (AOR = 1.76; 95% CI, 1.02-3.03), and with a heart disease (AOR = 1.59; 95% CI, 1.18-2.15). DPP4I use was not affected by the presence of joint pain.
本研究的目的是探讨二肽基肽酶-4抑制剂（DPP4Is）与2型糖尿病（T2DM）成人患者关节疼痛之间的关联。这是一项回顾性横断面研究设计，汇总了2012年和2014年医疗支出面板调查的数据。样本包括4559名年龄超过40岁的T2DM患者，其中有（n = 3224）或无关节疼痛（n = 1335）。采用卡方检验和逻辑回归来描述DPP4I使用与关节疼痛之间的关联。在患有T2DM的成年人中，70.7%报告有医生诊断的关节疼痛。有或无关节疼痛的患者在DPP4I使用方面无显著差异（7.8%对6.3%）。即使在调整了可能影响DPP4I使用的其他因素后，有或无关节疼痛的T2DM成年人在DPP4I使用方面也没有统计学上的显著差异（比值比[AOR]=1.04；95%置信区间[CI]，0.74 - 1.48）。有公共医疗保险的成年人（AOR = 1.76；95% CI，1.01 - 3.04）、有处方药保险的成年人（AOR = 1.76；95% CI，1.02 - 3.03）以及患有心脏病的成年人（AOR = 1.59；95% CI，1.18 - 2.15）。DPP4I的使用不受关节疼痛的影响。
